REVIEW article
Front. Cardiovasc. Med.
Sec. Cardiovascular Metabolism
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1570008
This article is part of the Research TopicThe Role of Gut Microbiome Metabolites in Cardiometabolic DisordersView all articles
Interactions between Gut Microbiota and Cardiovascular Drugs: Effects on Drug Therapeutic Effect and Side Effect
Provisionally accepted
- 1Shandong University, Jinan, China
- 2Key Laboratory of Cardiovascular Remodeling and Function Research, Qilu Hospital, Shandong University, Jinan, Shandong Province, China
- 3Department of Cardiology, Qilu Hospital of Shandong University, Jinan, Shandong Province, China
- 4Department of Gynecology, Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
There exists a complex relationship between gut microbiota and cardiovascular diseases (CVD). On one hand, the plasma levels of various metabolites produced by gut microbiota, such as trimethylamine n-oxide (TMAO), short-chain fatty acid (SFCA), bile acid (BA), are closely related to the occurrence and development of CVD. On the other hand,CVD can affect gut microbiota, leading to gut microbiota dysbiosis or metabolic changes. Cardiovascular drugs are the cornerstone of treating CVD, especially oral medications that play an indispensable role in the long-term treatment of chronic CVD. Increasing research suggests that drugs entering the gastrointestinal environment interact with gut microbiota. Due to the individual differences in gut microbiota, the exploration of its mechanisms is insufficient. Therefore, the purpose of this review is to summarize the interactions between various common cardiovascular drugs and gut microbiota, and to highlight the impact of the gut microbiota on the therapeutical effects and side effects of cardiovascular drugs.
Keywords: Gut Microbiota, Cardiovascular Diseases, drugs, Aspirin, statin
Received: 02 Feb 2025; Accepted: 27 Jun 2025.
Copyright: © 2025 Wang, Lan, Deng, Han, Zhang and Zhong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jingquan Zhong, Key Laboratory of Cardiovascular Remodeling and Function Research, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.